Back

β2-Adrenergic Signaling Switches from Cardioprotective to Cardiotoxic in Acute vs. Chronic Oxidative Stress

Fajardo, G.; Zhao, M.; jung, G.; Rajagopalan, V.; Coronado, M.; Reddy, S.; Bernstein, D.

2026-04-29 cell biology
10.64898/2026.04.22.720269 bioRxiv
Show abstract

BACKGROUND AND PURPOSE{beta}-adrenergic receptors (AR) regulate both cardiac function and remodeling. Many studies suggest that, in addition to their effects on heart rate and contractility, {beta}1-ARs mediate cardiotoxic signaling, whereas {beta}2-ARs are generally cardioprotective. However, there is conflicting data on the role of {beta}2-ARs, differing dependent on the nature of the stress. Given the extremely common use of {beta}-blockers and agonists clinically, we sought to understand the differential cardioprotective/cardiotoxic effects of {beta}2-AR signaling dependent on timing (acute vs. chronic) and type of cardiotoxic stress. EXPERIMENTAL APPROACHWild-type (WT) and {beta}-AR knockout ({beta}1-KO and {beta}2-KO) mice were subjected to acute (15 mg{middle dot}kg-1 x 1 dose) or chronic (2 mg{middle dot}kg-1{middle dot}wk-1 x 7 wks) oxidative stress using doxorubicin (DOX). Survival, cardiac function and histopathology were assessed and differential signaling activation determined by Western blot and gene expression by RNA-seq. KEY RESULTSWe have shown that {beta}2-KOs manifest extreme cardiotoxicity with acute DOX (100% mortality within 30 min), supporting a strong cardioprotective role of {beta}2-signaling. In marked contrast, with chronic DOX, {beta}2-KO had enhanced survival (t[1/2] 54 d vs. 42 d in WT) and attenuated cardiac dysfunction. In {beta}2-KO, acute DOX activated stress MAPKs (p38, ERK and JNK), whereas chronic DOX did not; furthermore, in the absence of {beta}2-ARs, oxidative stress and lipid accumulation were reduced, genes regulating compensatory metabolic pathways (AMPK and insulin/PI3K) were upregulated, and genes regulating mitochondrial and contractile function were preserved, whereas they were downregulated in WT with chronic DOX. CONCLUSIONS{beta}2-AR signaling switches from being cardioprotective during acute oxidative stress, to cardiotoxic during chronic stress. Inhibition of {beta}2-AR signaling during chronic stress induces signaling and metabolic compensations that serve to reduce oxidative injury. This unexpected temporal switching has potential significant implications for all models of cardiovascular disease, as well as for the clinical use of subtype-specific {beta}-blockers. CLINICAL PERSPECTIVEO_ST_ABSWhat is new?C_ST_ABSO_LIOur finding that {beta}2-adrenergic receptor signaling can switch from being beneficial (cardioprotective) to detrimental (cardiotoxic) depending on the acuteness or chronicity of a cardiac stressor. C_LIO_LIIdentification of the mechanisms by which this temporal switch is mediated could lead to new drug development. C_LI What are the clinical implications?O_LIOur findings provide potential guidance in choosing between a {beta}1-specific vs. a {beta}1/2-non-specific drug when treating specific cardiovascular diseases based on their temporal characteristics. C_LIO_LIThe temporal protective/toxic switching that we describe could be a mechanism common to many other drugs, yet is rarely tested, suggesting the need for additional studies using temporal course as a factor. C_LI

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of the American Heart Association
119 papers in training set
Top 0.2%
19.0%
2
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.1%
10.6%
3
Circulation
66 papers in training set
Top 0.4%
9.3%
4
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 0.4%
8.6%
5
PLOS ONE
4510 papers in training set
Top 22%
8.4%
50% of probability mass above
6
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.2%
6.9%
7
Frontiers in Pharmacology
100 papers in training set
Top 1%
2.8%
8
Scientific Reports
3102 papers in training set
Top 44%
2.6%
9
Circulation Research
39 papers in training set
Top 0.5%
2.1%
10
The American Journal of Cardiology
15 papers in training set
Top 0.9%
1.7%
11
Physiological Reports
35 papers in training set
Top 0.5%
1.7%
12
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.4%
13
Frontiers in Physiology
93 papers in training set
Top 4%
1.2%
14
Cardiovascular Research
33 papers in training set
Top 0.7%
1.0%
15
Atherosclerosis
29 papers in training set
Top 0.9%
1.0%
16
JACC: Basic to Translational Science
15 papers in training set
Top 0.3%
1.0%
17
International Journal of Molecular Sciences
453 papers in training set
Top 12%
0.9%
18
Circulation: Heart Failure
14 papers in training set
Top 0.4%
0.8%
19
Heart
10 papers in training set
Top 0.9%
0.8%
20
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.4%
0.8%
21
Frontiers in Endocrinology
53 papers in training set
Top 2%
0.8%
22
iScience
1063 papers in training set
Top 36%
0.7%
23
Cells
232 papers in training set
Top 8%
0.5%
24
European Heart Journal
16 papers in training set
Top 1%
0.5%
25
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.5%
26
Toxicology and Applied Pharmacology
13 papers in training set
Top 0.3%
0.5%